Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).
Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.
Growing demand for biologic fill/finish services will see the market develop at a fast pace moving toward 2030, with a number of companies investing heavily in the area.
Fujifilm Diosynth has developed its ability to transition products from research to GMP, answering a big challenge as more parties look to get involved in the space, says COO.
Fujifilm Diosynth announces the inception of its FDB center of excellence in bioprocessing 2.0 to extend its bioprocessing innovations with a network of researchers.
Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.
Fujifilm has launched a mammalian cell line it says can deliver titers up to 3g/L before subsequent optimisation and will complement its microbial-based platform.
The Japanese joint venture between Dr. Reddy’s and Fujifilm has been called-off though both say future collaboration remains likely, especially in API production.
